The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations

International Journal of Tuberculosis and Lung Disease

Volumn 5, Issue 8, 2001, Pages 691-695

  Pillai, G ^a   Ellard, G A ^a   Smith, P J ^a   Fourie, P B ^a  

^a King George V Hospital Durban   (South Africa)

Author keywords

Fixed dose combination; Relative bioavailability; Rifampicin; Tuberculosis; Urinary excretion

Indexed keywords

DEACETYLRIFAMPICIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAMPICIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COLORIMETRY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC VALUE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NON INVASIVE MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS; URINARY EXCRETION;

ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORIMETRY; CROSS-OVER STUDIES; DRUG COMBINATIONS; ETHAMBUTOL; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; QUALITY CONTROL; REFERENCE VALUES; RIFAMPIN; THERAPEUTIC EQUIVALENCY; TUBERCULOSIS; URINALYSIS;

EID: 0034906127     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity of ensuring optimal absorption
2. Compliance of patients and physicians: Experience and lessons from tuberculosis
3. Acceptability, compliance and adverse reactions when isoniazid, rifampin and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy
4. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide
5. Assessment of a daily combined preparation of isoniazid, rifampin and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis
6. Mechanisms of drug action in short course chemotherapy
7. Recent bioequivalence studies on fixed dose combination (FDC) antituberculosis drug formulations available on the global market
8. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts; a new method of drug assessment
9. The promise and reality of fixed-dose combinations with rifampicin
10. Assuring bioavailability of fixed-dose combinations of antituberculosis medications
11. A standardized screening protocol for the in vivo assessment of rifampicin bioavailability
12. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability
13. The bioavailability of isoniazid, rifampicin and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis
14. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after simultaneous extraction from plasma
15. Metabolic study and controlled clinical trials of rifampin
16. A distribution-free procedure for the statistical analysis of bioequivalence studies
17. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of antituberculosis drugs; procedures for ensuring laboratory proficiency